Literature DB >> 11751972

How H13 histocompatibility peptides differing by a single methyl group and lacking conventional MHC binding anchor motifs determine self-nonself discrimination.

David A Ostrov1, Matthew M Roden, Wuxian Shi, Edith Palmieri, Gregory J Christianson, Lisa Mendoza, Gilbert Villaflor, Darcie Tilley, Nilabh Shastri, Howard Grey, Steven C Almo, Derry Roopenian, Stanley G Nathenson.   

Abstract

The mouse H13 minor histocompatibility (H) Ag, originally detected as a barrier to allograft transplants, is remarkable in that rejection is a consequence of an extremely subtle interchange, P4(Val/Ile), in a nonamer H2-D(b)-bound peptide. Moreover, H13 peptides lack the canonical P5(Asn) central anchor residue normally considered important for forming a peptide/MHC complex. To understand how these noncanonical peptide pMHC complexes form physiologically active TCR ligands, crystal structures of allelic H13 pD(b) complexes and a P5(Asn) anchored pD(b) analog were solved to high resolution. The structures show that the basis of TCRs to distinguish self from nonself H13 peptides is their ability to distinguish a single solvent-exposed methyl group. In addition, the structures demonstrate that there is no need for H13 peptides to derive any stabilization from interactions within the central C pocket to generate fully functional pMHC complexes. These results provide a structural explanation for a classical non-MHC-encoded H Ag, and they call into question the requirement for contact between anchor residues and the major MHC binding pockets in vaccine design.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751972     DOI: 10.4049/jimmunol.168.1.283

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Mapping and restriction of a dominant viral CD4+ T cell core epitope by both MHC class I and MHC class II.

Authors:  Dirk Homann; Hanna Lewicki; David Brooks; Jens Eberlein; Valerie Mallet-Designé; Luc Teyton; Michael B A Oldstone
Journal:  Virology       Date:  2007-02-21       Impact factor: 3.616

2.  Recognition of allo-peptide is governed by novel anchor imposition and limited variations in TCR contact residues.

Authors:  Corbett J A Reinbold; Subramaniam Malarkannan
Journal:  Mol Immunol       Date:  2007-11-05       Impact factor: 4.407

3.  Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide.

Authors:  Eliada Lazoura; Jodie Lodding; William Farrugia; Paul A Ramsland; James Stevens; Ian A Wilson; Geoffrey A Pietersz; Vasso Apostolopoulos
Journal:  Immunology       Date:  2006-11       Impact factor: 7.397

4.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

Authors:  Mahesh Yadav; Suchit Jhunjhunwala; Qui T Phung; Patrick Lupardus; Joshua Tanguay; Stephanie Bumbaca; Christian Franci; Tommy K Cheung; Jens Fritsche; Toni Weinschenk; Zora Modrusan; Ira Mellman; Jennie R Lill; Lélia Delamarre
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

5.  A methods paper that led to much more.

Authors:  Derry Roopenian
Journal:  J Immunol       Date:  2014-01-01       Impact factor: 5.422

Review 6.  H60: A Unique Murine Hematopoietic Cell-Restricted Minor Histocompatibility Antigen for Graft-versus-Leukemia Effect.

Authors:  Eun Young Choi; Kyungho Choi; Giri Nam; Woojin Kim; Minho Chung
Journal:  Front Immunol       Date:  2020-06-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.